Oncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types

MT Newswires Live

2025/07/16

Oncolytics Biotech (ONCY) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.

The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.

Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically "cold" tumors into "hot" phenotypes, paving the way for registration-enabling trials.

Shares were up 2.7% in recent early trading.

Price: 1.16, Change: +0.03, Percent Change: +2.65

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551812513"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551812513\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551812513?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551812513","market":"nz","top_or_hot":-1,"title":"Oncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech</a> (ONCY) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.</p><p>The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.</p><p>Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically \"cold\" tumors into \"hot\" phenotypes, paving the way for registration-enabling trials.</p><p>Shares were up 2.7% in recent early trading.</p><p>Price: 1.16, Change: +0.03, Percent Change: +2.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-16 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech</a> (ONCY) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.</p><p>The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.</p><p>Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically \"cold\" tumors into \"hot\" phenotypes, paving the way for registration-enabling trials.</p><p>Shares were up 2.7% in recent early trading.</p><p>Price: 1.16, Change: +0.03, Percent Change: +2.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCY","symbol_name":"Oncolytics Biotech Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2551812513","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551812513","pubTimestamp":1752673388,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oncolytics Biotech  said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically \"cold\" tumors into \"hot\" phenotypes, paving the way for registration-enabling trials.Shares were up 2.7% in recent early trading.Price: 1.16, Change: +0.03, Percent Change: +2.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONCY":"Oncolytics Biotech Inc","BK4139":"生物科技"},"translate_title":"Oncolytics Biotech表示Pelareorep数据显示对多种肿瘤类型有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCY":0.9},"content_text":"Oncolytics Biotech (ONCY) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically \"cold\" tumors into \"hot\" phenotypes, paving the way for registration-enabling trials.Shares were up 2.7% in recent early trading.Price: 1.16, Change: +0.03, Percent Change: +2.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}